Li Zhi, Wang Jin, Chen Hui-Bing, Guo Xiao-Mei, Chen Xiao-Ping, Wang Meng, Dong Li-Juan, Zhang Min-Min
Department of Nursing, Zhongshan Hospital of Chinese Traditional Medicine, Zhongshan 528400, China.
Department of Nephrology, Zhongshan Hospital of Chinese Traditional Medicine, Zhongshan 528400, China.
J Oncol. 2021 Nov 26;2021:3003951. doi: 10.1155/2021/3003951. eCollection 2021.
MicroRNA-423 (miR-423) rs6505162 polymorphism is found to be associated with breast cancer (BC) risk. However, the results were inconsistent. This study meta-analyzed the literature on possible association between rs6505162 polymorphism and BC risk.
PubMed, Embase, Google Scholar, and the Chinese National Knowledge Infrastructure (CNKI) databases were systematically searched to identify relevant studies. Meta-analyses were performed to examine the association between rs6505162 polymorphism and BC.
None of the five genetic models suggested a significant association between rs6505162 polymorphism and BC risk: allelic model, OR 1.02, 95% CI 0.18-1.28, =0.85; recessive model, OR 0.99, 95% CI 0.72-1.38, =0.97; dominant model, OR 0.93, 95% CI 0.72-1.21, =0.60; homozygous model, OR 1.04, 95% CI 0.66-1.65, =0.87; and heterozygous model, OR 1.07, 95% CI 0.90-1.28, =0.45. Similar results were obtained in subgroup analyses of Asian, Chinese, and Caucasian patients.
The available evidence suggests no significant association between rs6505162 polymorphism and BC risk. These conclusions should be verified in large, well-designed studies.
微小RNA-423（miR-423）rs6505162多态性被发现与乳腺癌（BC）风险相关。然而，结果并不一致。本研究对关于rs6505162多态性与BC风险之间可能关联的文献进行了荟萃分析。
系统检索了PubMed、Embase、谷歌学术和中国国家知识基础设施（CNKI）数据库以识别相关研究。进行荟萃分析以检验rs6505162多态性与BC之间的关联。
五种遗传模型均未表明rs6505162多态性与BC风险之间存在显著关联：等位基因模型，比值比（OR）为1.02，95%置信区间（CI）为0.18 - 1.28，P = 0.85；隐性模型，OR为0.99，95% CI为0.72 - 1.38，P = 0.97；显性模型，OR为0.93，95% CI为0.72 - 1.21，P = 0.60；纯合子模型，OR为1.04，95% CI为0.66 - 1.65，P = 0.87；杂合子模型，OR为1.07，95% CI为0.90 - 1.28，P = 0.45。在亚洲、中国和白种人患者的亚组分析中也获得了类似结果。
现有证据表明rs6505162多态性与BC风险之间无显著关联。这些结论应在大型、设计良好的研究中得到验证。
